BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical hol

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweig

Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earni

Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free R

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) traded up 5.2% during mid-day tradin

Danish drugmaker H Lundbeck A/S has expressed interest ​in acquiring Chicago-based Xeris Biopharma ,

- Bloomberg 

U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securit

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average r

Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outp

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to

Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 20

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received an average recommendati

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth ac

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweig

Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a y

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the q

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed t

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 mi

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The lates

Please replace the release issued earlier today with the following corrected version that provides a

Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $375.000 million-$390.000 mi

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.01 per share which beat the

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS)

Xeris Biopharma Holdings (NASDAQ:XERS) sees FY2026 sales of $375.000 million-$390.000 million vs $36

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the

Xeris Biopharma Holdings shares are falling Friday after the company announced a patent infringement

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS)

Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) wit